Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bocidelpar - Mitobridge

Next Previous
Drug Profile

Bocidelpar - Mitobridge

Alternative Names: ASP-0367; MA-0211; MTB-1

Latest Information Update: 22 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mitobridge
  • Developer Astellas Pharma; Mitobridge
  • Class Fluorinated hydrocarbons; Hexanoic acids; Imidazoles; Phenyl ethers; Small molecules; Urologics
  • Mechanism of Action Peroxisome proliferator-activated receptor delta modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Mitochondrial myopathies
  • Phase II Chronic fatigue syndrome
  • Phase I Duchenne muscular dystrophy
  • No development reported Metabolic disorders
  • Discontinued Hypoxia

Most Recent Events

  • 03 Jul 2025 Astellas Pharma terminates a phase II MOUNTAINSIDE trial in Mitochondrial myopathies in USA (PO) due to failure to meet the pre-specified criteria for efficacy (NCT04641962)
  • 16 Feb 2024 phase-I development in Duchenne muscular dystrophy is ongoing in USA (PO)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In adolescents, In children) in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top